Shares of MediWound Ltd. (NASDAQ:MDWD) have been given an average rating of “Buy” by the six analysts that are covering the company. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.25.

MDWD has been the subject of several research analyst reports. Jefferies Group reduced their target price on MediWound from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, July 29th. Zacks Investment Research cut MediWound from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Finally, Wells Fargo & Co. started coverage on MediWound in a research note on Wednesday, August 17th. They set an “outperform” rating and a $14.00 price objective on the stock.

Shares of MediWound (NASDAQ:MDWD) remained flat at $5.40 on Monday. The company had a trading volume of 11,533 shares. The company has a 50-day moving average of $6.49 and a 200-day moving average of $7.41. MediWound has a 12 month low of $5.10 and a 12 month high of $10.47. The stock’s market capitalization is $118.10 million.

MediWound (NASDAQ:MDWD) last released its earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.26) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.26). The company earned $0.52 million during the quarter, compared to analysts’ expectations of $0.61 million. MediWound had a negative return on equity of 148.23% and a negative net margin of 1,776.06%. The business’s revenue was up 420.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.17) EPS. Equities analysts anticipate that MediWound will post ($0.99) earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of MDWD. Citadel Advisors LLC boosted its stake in MediWound by 4.5% in the third quarter. Citadel Advisors LLC now owns 33,622 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 1,456 shares during the last quarter. United Services Automobile Association boosted its stake in MediWound by 1.3% in the third quarter. United Services Automobile Association now owns 125,080 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 1,640 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in MediWound during the third quarter worth about $116,000. Wells Fargo & Company MN bought a new stake in MediWound during the third quarter worth about $202,000. Finally, Wellington Management Group LLP boosted its stake in MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock worth $8,431,000 after buying an additional 100,723 shares during the last quarter. Institutional investors own 27.49% of the company’s stock.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.

5 Day Chart for NASDAQ:MDWD

Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.